Advances in Cancer Immunotherapy™:
A Focus on MSI-High and TMB-High Cancers

Program Learning Objectives 

• Identify the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers.
• Summarize recent updates in cancer immunotherapy for MSI-H/TMB-H cancers and toxicity management for key disease states.
• Implement cancer immunotherapy for MSI-H/TMB-H cancer into clinical practice appropriately.
• Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers.

This program has already taken place:
Wednesday, Nov. 3, 2021
4-8 p.m. CDT
Hosted on Zoom Webinar

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for MSI-high/TMB-high cancers.

Organizers:

Michael Morse, MD – Duke University Medical Center
Michael Overman, MD – The University of Texas MD Anderson Cancer Center

Program Agenda

Please note that enduring materials from the program will only be available to those who attend the live program.

Case Study Submission Information:
To submit closed/past case studies for live expert panel feedback, please indicate your interest in the checkbox in program registration and SITC staff will follow up with you through email with further instruction.

Target Audience
The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Continuing Pharmacy Education

Postgraduate Institute of Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.

View the SITC Meeting Code of Conduct.

The ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of 10/13/2021)